Cancer Gene Therapy Market Overview:
Cancer Gene Therapy Market was valued at $289 million in 2016, and is estimated to reach $2,082 million by 2023, registering a CAGR of 32.4% from 2017 to 2023. With the advancement in technology, the gene therapy market has transformed during the recent few years. Cancer gene therapy is a technique used for the treatment of cancer where therapeutic DNA is being introduced into the gene of the patient with cancer.
Due to the high success rate during the preclinical and clinical trial, cancer gene therapy is gaining popularity. There are many techniques used for cancer gene therapy, for example, a procedure where the mutated gene is being replaced with a healthy gene or inactivation of gene whose function is abnormal. Recently, a new technique has been developed, where new genes are introduced into the body to help fight against cancer cells.
The global cancer gene therapy market is segmented based on therapy, end user, and geography. Based on therapy, it is categorized into gene induced immunotherapy, oncolytic virotherapy, and gene transfer. Gene induced immunotherapy is further segmented into delivery of cytokines gene and delivery of tumor antigen gene.
Oncolytic virotherapy is further categorized into adenovirus, lentivirus, retro virus, adeno associated virus, herpes simplex virus, alpha virus, vaccinia virus, simian virus, and others. Gene transfer is further classified into naked plasmid vector, electroporation, sonoportion, magnetofection, and gene gun. Based on geography, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Drivers, Restraints, and Opportunities
The impact of the driving factors is expected to overcome the effect of restraints. Moreover, the technological advancements leading to higher adoption rate and untapped markets in developing economies are expected to provide new avenues for the growth of cancer gene therapy market in the near future
Drivers and Restraints
Cancer gene therapy Market: Key Geographic Segment
North America accounted for the largest market share in the cancer gene therapy market in 2016, and is expected to retain its dominance throughout the forecast period.
Cancer Gene Therapy Market, by Region, 2016 (%)
The key players operating in the global cancer gene therapy market include Adaptimmune, GlaxoSmithKline, Bluebird bio, Inc., Merck, Celgene, Shanghai Sunway Biotech, BioCancell, Shenzhen SiBiono GeneTech, SynerGene Therapeutics, and OncoGenex Pharmaceuticals.
Other prominent players in the value chain include Genelux Corporation, Cell Genesys, Advantagene, GenVec, BioCancell, Celgene, Epeius Biotechnologies, Introgen Therapeutics, Ziopharm Oncology, Shenzhen SiBiono GeneTech, and Altor Bioscience.
- This report entails a detailed quantitative analysis of the current market trends from 2016 to 2023 to identify the prevailing opportunities.
- Market estimations are based on comprehensive analysis of the key developments in the industry.
- In-depth analysis, based on geography assists in understanding the regional market to assist in strategic business planning.
- The development strategies adopted by key manufacturers are enlisted to understand the competitive scenario of the market.
Cancer Gene Therapy Market Key Segments:
- Gene Induced Immunotherapy
- Delivery of Cytokines Gene
- Delivery of Tumor Antigen Gene
- Oncolytic Virotherapy
- Retro Virus
- Adeno Associated Virus
- Herpes Simplex Virus
- Alpha Virus
- Vaccinia Virus
- Simian Virus
- Gene Transfer
- Naked/Plasmid Vectors
- Gene Gun
By End User
- Diagnostics Centers
- Research Institutes
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Republic of South Africa
- Saudi Arabia
- Rest of LAMEA